Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.

@article{Kratochvil2003AtomoxetineAS,
  title={Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.},
  author={Christopher J. Kratochvil and Brigette S Vaughan and Martin J Harrington and William M. J. Burke},
  journal={Expert opinion on pharmacotherapy},
  year={2003},
  volume={4 7},
  pages={1165-74}
}
Atomoxetine (Strattera, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far, two open-label and seven randomised, double-blind, placebo-controlled, clinical trials have been published, six in youths and three in adults. Each of these trials has shown a positive response as measured by the primary efficacy measures, the ADHD-IV Rating Scale (ADHD RS) or the Conners Adult ADHD… CONTINUE READING
38 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…